Orchasp Limited has successfully launched its electronic health records platform INDUSAYUSH on the Apple App Store, marking a significant milestone in the company's digital healthcare expansion. The announcement was made on February 24, 2026, through a regulatory filing under SEBI's disclosure requirements.

Platform Launch Details

The company formally disclosed the development pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The INDUSAYUSH platform has been admitted to the Apple App Store with effect from February 24, 2026, making it accessible to iOS users worldwide.

Official Apple Confirmation

Apple has officially confirmed the app's approval through App Store Connect, congratulating Orchasp Limited on the successful distribution approval. The tech giant noted that while the app has been approved, it can take up to 24 hours for applications to become fully available on the App Store after release.

The approval email from Apple's App Review team emphasized the global reach opportunity that the App Store provides, highlighting features such as:

• App Analytics for measuring user engagement
• Marketing guidelines for App Store promotion
• Search Ads capabilities for enhanced visibility

Digital Healthcare Expansion

The INDUSAYUSH platform represents Orchasp Limited's strategic move into the digital healthcare sector, specifically focusing on electronic health records management. The platform's availability on iOS devices expands the company's potential user base significantly, given Apple's substantial market presence in the mobile ecosystem.

The regulatory filing was signed by P. Chandra Sekhar, Managing Director & CFO (DIN: 01647212), emphasizing the strategic importance of this development for the company's stakeholders and investors.

Market Implications

With the INDUSAYUSH app now available on Apple's platform, Orchasp Limited positions itself to compete in the growing digital health records market. The Apple App Store's global distribution network provides the company with immediate access to millions of potential users across international markets, potentially driving user adoption and revenue growth in the healthcare technology segment.

Orchasp Limited announced the outcome of its Board Meeting held on February 10, 2026, where directors approved unaudited financial results for the quarter ended December 31, 2025, and made significant board appointments. The company submitted comprehensive regulatory filings to BSE and NSE under SEBI (LODR) Regulations, 2015.

Financial Performance Overview

The company's Q3FY26 financial results showed mixed performance compared to the previous year. Net profit declined to Rs. 19.03 lakhs from Rs. 50.10 lakhs in Q3FY25, while revenue from operations decreased significantly.

Nine-Month Performance Turnaround

Despite quarterly challenges, the nine-month performance demonstrated remarkable recovery. The company achieved net profit of Rs. 94.02 lakhs compared to a substantial loss of Rs. 1,354.63 lakhs in the corresponding period of the previous year.

Board Appointments and Leadership Changes

The Board approved two key appointments effective February 10, 2026. Mr. Srinivasu Sunkara (DIN: 11509166) was appointed as Independent Director for five years (February 10, 2026 to February 9, 2031). He brings 21 years of global experience in digital technology leadership across healthcare, retail, supply chain, and financial domains, holding a Master's degree in Computer Science and Ph.D. in Data Mining from Andhra University.

Ms. Sirisha Pattapurathi was appointed as non-executive non-independent woman director. She holds an MBA in Technology Management from The University of Sheffield, UK, with 19 years of experience in finance, vendor operations, and supplier management at Microsoft. She is the sister of Mr. Chandra Sekhar Pattapurathi, the company's Managing Director and CFO.

Independent Directors' Tenure Completion

Three independent directors will complete their tenures shortly. Ms. Ponnari Gottipati (DIN: 09075036) will cease to be Independent Director on February 12, 2026, after completing her first term due to pre-occupational and personal reasons. Mr. Bade Srinivasa Reddy (DIN: 01384074) and Mr. Sai Roopkumar Vegunta (DIN: 05317482) will complete their second consecutive terms on March 6, 2026.

Committee Restructuring

Consequent to the appointments and tenure completions, the Board approved reconstitution of various committees effective February 10, 2026. The Audit Committee now comprises Mr. Sai Roopkumar Vegunta as Chairperson, with Mr. Srinivasu Sunkara and Mr. Ravikishore Vithaleswara Brahmananda Bhattiprolu as members. The Nomination and Remuneration Committee and Stakeholders Relationship Committee compositions remain unchanged.

Regulatory Compliance and Auditor Observations

JMT & Associates expressed qualified opinions on both standalone and consolidated financial results. Key concerns include the Rs. 6,825 lakhs investment in wholly-owned subsidiary Cybermate International, Unipessoal, LDA in Portugal, which has remained non-operational for over four years with Portuguese authorities issuing cancellation notice for Certificate of Incorporation. The company incorporated new wholly-owned subsidiary Orchasp Inc in USA on December 9, 2025, and plans to transfer investments from Portuguese entity.

The Board meeting commenced at 11:00 AM IST and concluded at 3:00 PM IST on February 10, 2026. The company completed preferential allotment of 2,68,75,000 equity shares of Rs. 2 each at Rs. 3.20 per share on December 18, 2025, with shares admitted for listing on BSE and NSE on January 28, 2026.